Following adults with myelofibrosis treated with ruxolitinib over time
Studies how blood and clinical features affect long-term survival in myelofibrosis patients on ruxolitinib.
Plain-language title generated from the registry record
Registry title: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
Key facts
- Where
- Bologna, Cagliari, Catania, Cosenza, Ferrara, Genoa, Milan, Monza, Naples, Padova, Parma, Pesaro, Piacenza, Ravenna, Reggio Calabria, Rimini, Rome, Siena, Turin, Udine, Verona, and Viterbo, ItalySee the 26 sites
Where in Italy
- IRCCS Policlinico Sant'OrsolaBologna, ItalyTaking people
- Ospedale "A. Businco" - Dipartimento Scienze Mediche e Sanità Pubblica Università degli Studi di CagliariCagliari, ItalyTaking people
- A.O.U. "Policlinico-V. Emanuele"- P.O. FerrarottoCatania, ItalyTaking people
- Azienda Ospedaliera AnnunziataCosenza, ItalyTaking people
- Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. AnnaFerrara, ItalyTaking people
- IRCCS Azienda Ospedaliera Universitaria "San Martino" - ISTGenoa, ItalyTaking people
- Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
- Ospedale San GerardoMonza, ItalyTaking people
- Università degli Studi di Napoli Federico II U.O.C. di Ematologia e Trapianti di midolloNaples, ItalyTaking people
- AOU di PadovaPadova, ItalyTaking people
- Azienda Ospedaliero Universitaria di ParmaParma, ItalyTaking people
- A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San SalvatorePesaro, ItalyTaking people
- AUSL di Piacenza - Palazzine Medicine SpecialistichePiacenza, ItalyTaking people
- Dipartimento Oncoematologico - AUSL della RomagnaRavenna, ItalyTaking people
- Grande Ospedale Metropolitano Bianchi Melacrino MorelliReggio Calabria, ItalyTaking people
- Ospedale "Infermi" di RiminiRimini, ItalyTaking people
- A.O.U. Policlinico Umberto I - Università degli Studi di Roma "La Sapienza"Rome, ItalyTaking people
- Ospedale S. EugenioRome, ItalyTaking people
- Policlinico S.Maria alle ScotteSiena, ItalyTaking people
- A. O. Ordine Mauriziano di TorinoTurin, ItalyTaking people
- Città della Salute e della ScienzaTurin, ItalyTaking people
- Department of Oncology, University of TorinoTurin, ItalyTaking people
- Ospedale San Luigi Gonzaga - Regione GonzoleTurin, ItalyTaking people
- A.O.U. Integrata di UdineUdine, ItalyTaking people
- A.O.U. Integrata VeronaVerona, ItalyTaking people
- Ospedale BelcolleViterbo, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT06516406
- Record updated
- 5 December 2024
- Original description
The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.Read full original descriptionShow less
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.
Inclusion: Age ≥ 18 years; Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice; Availability of data on clinical history prior to initiation of Ruxolitinib therapy; Obtaining informed consent for data collection and processing.
Exclusion: None.